Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00240344
Other study ID # NL401142
Secondary ID REALISTIC
Status Completed
Phase Phase 4
First received October 16, 2005
Last updated August 29, 2011
Start date September 2004
Est. completion date February 2008

Study information

Verified date August 2011
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority European Union: European Medicines Agency
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.


Recruitment information / eligibility

Status Completed
Enrollment 2650
Est. completion date February 2008
Est. primary completion date February 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- High risk patients

- High doses of other statins

- LDL-C known, starts with Crestor 10 mg

- Permission to use patient data by AstraZeneca (AZ)

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands Research Site Alkmaar
Netherlands Research Site Almelo
Netherlands Research Site Alphen Aan Den Rijn
Netherlands Research Site Amsterdam
Netherlands Research Site Apeldoorn
Netherlands Research Site Assen
Netherlands Research Site Bergen Op Zoom
Netherlands Research Site Beverwijk
Netherlands Research Site Bilthoven
Netherlands Research Site Blaricum
Netherlands Research Site Boxmeer
Netherlands Research Site Breda
Netherlands Research Site Brunssum
Netherlands Research Site Capelle Aan Den Ijssel
Netherlands Research Site Delft
Netherlands Research Site Delfzijl
Netherlands Research Site Den Helder
Netherlands Research Site Dirksland
Netherlands Research Site Doetinchem
Netherlands Research Site Dokkum
Netherlands Research Site Dordrecht
Netherlands Research Site Drachten
Netherlands Research Site Ede Gld
Netherlands Research Site Eindhoven
Netherlands Research Site Emmen
Netherlands Research Site Enschede
Netherlands Research Site Etten-leur
Netherlands Research Site Geldrop
Netherlands Research Site Gouda
Netherlands Research Site Groningen
Netherlands Research Site Haarlem
Netherlands Research Site Hardenberg
Netherlands Research Site Heerenveen
Netherlands Research Site Heerlen
Netherlands Research Site Helmond
Netherlands Research Site Hengelo Ov
Netherlands Research Site Hoofddorp
Netherlands Research Site Hoogeveen
Netherlands Research Site Hoorn Nh
Netherlands Research Site Ijmuiden
Netherlands Research Site Landsmeer
Netherlands Research Site Leiden
Netherlands Research Site Lelystad
Netherlands Research Site Maastricht
Netherlands Research Site Meppel
Netherlands Research Site Oosterhout Nb
Netherlands Research Site OSS
Netherlands Research Site Purmerend
Netherlands Research Site Roermond
Netherlands Research Site Roosendaal
Netherlands Research Site Rotterdam
Netherlands Research Site S-gravenhage
Netherlands Research Site S-hertogenbosch
Netherlands Research Site Schiedam
Netherlands Research Site Sneek
Netherlands Research Site Spijkenisse
Netherlands Research Site Stadskanaal
Netherlands Research Site Terneuzen
Netherlands Research Site Tiel
Netherlands Research Site Tilburg
Netherlands Research Site Utrecht
Netherlands Research Site Veghel
Netherlands Research Site Veldhoven
Netherlands Research Site Venlo
Netherlands Research Site Vlaardingen
Netherlands Research Site Vlissingen
Netherlands Research Site Waalwijk
Netherlands Research Site Weert
Netherlands Research Site Winschoten
Netherlands Research Site Winterswijk
Netherlands Research Site Zaandam
Netherlands Research Site Zevenaar
Netherlands Research Site Zoetermeer
Netherlands Research Site Zutphen
Netherlands Research Site Zwolle

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Netherlands, 

See also
  Status Clinical Trial Phase
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Completed NCT01709513 - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) Phase 3
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02550288 - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Phase 3
Completed NCT03929198 - Translation of Pritikin Program to the Community N/A
Completed NCT04485793 - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia N/A
Completed NCT02341924 - Validating the "Foods for Health" Portfolio of Functional Food Products N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT01941836 - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients Phase 2
Completed NCT01934608 - The Effect of Synching Prescription Refills on Adherence N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01678521 - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients N/A
Completed NCT01670734 - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects Phase 1
Completed NCT01370590 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1) Phase 3
Completed NCT01370603 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1) Phase 3
Completed NCT01768403 - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia N/A
Completed NCT01446679 - Special Drug Use-Results Survey of Lipitor Tablets N/A
Completed NCT01575171 - Using Nudges to Implement Comparative Effectiveness N/A